**DC Bead® with doxorubicin**

Survival benefit confirmed with DC Bead®

![Graph](image)

“These data validate the safety of DEB-TACE [DEBDOX®] and show that the survival expectancy applying current selection criteria and technique is better than that previously reported.”


**DC Bead® Indications:**
- DC Bead is CE marked and is indicated for the treatment of malignant hypervascularised tumours.
- DC Bead is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC) after embolisation.
- DC Bead is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC) after embolisation and then, as a secondary action, elute a local, controlled and sustained dose to the tumours.

**Cautions:**
- DC Bead® and DC Bead® are manufactured by Biocompatibles UK Ltd. and are not cleared by the FDA for sale or distribution in the USA.
- Exceeding a loading dose of 37.5 mg doxorubicin per 1 ml DC Bead® may lead to some systemic distribution of doxorubicin and related side effects.
- Exceeding this amount may lead to some systemic distribution of doxorubicin and related side effects.
- Exceeding this amount may lead to some systemic distribution of doxorubicin and related side effects.
- Exceeding this amount may lead to some systemic distribution of doxorubicin and related side effects.

**Potential Complications:**
- Non-target embolisation
- Pulmonary embolism
- Thrombosis at an unsuitable location
- Capillary bed saturation and tissue damage
- Neurological deficits including cranial nerve palsy
- Venous thrombosis
- Death

**Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using DC Bead:**

<table>
<thead>
<tr>
<th>Overall Survival in BCLC-A and BCLC-B Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Median overall survival</strong></td>
</tr>
<tr>
<td><strong>Survival (months)</strong></td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>20</td>
</tr>
<tr>
<td>40</td>
</tr>
<tr>
<td>60</td>
</tr>
<tr>
<td>80</td>
</tr>
<tr>
<td>100</td>
</tr>
</tbody>
</table>

For more information on this article, scan here or visit: [www.dcbeadbibliography.co.uk/Burrel_Hepatology_2012](http://www.dcbeadbibliography.co.uk/Burrel_Hepatology_2012)
DEBDOX®: Delivering the standard of care in intermediate HCC

Survival benefit confirmed with DC Bead®

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Burrel_Hepatology_2012

Sustained drug release from DC Bead® confirmed by histological explant data

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Namur_Hepatology_2011

Improved efficacy vs conventional TACE, particularly in patients with advanced disease

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Song_EJGH_2011

DEBDOX® technical recommendations

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Lencioni_CVIR_2011

DEBDOX® with sorafenib is well tolerated, with excellent disease control

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Pawlik_JCO_2011

PRECISION V: Improved tolerability & efficacy in more challenging HCC patients

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Lammer_CVIR_2010

Improved outcomes over bland embolisation

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Malagari_CVIR_2010

Superior pharmacokinetic profile

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Varela_Hepatology_2007

DC Bead® and DC Bead®M are manufactured by Biocompatibles UK Ltd, Chapman House, Farnham Business Park, Weydon Lane, Farnham, Surrey, GU9 8QL, UK. DC Bead and DEBDOX are registered trademarks of Biocompatibles UK Ltd. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd. DC Bead and DC Bead® are not currently cleared by the FDA for sale or distribution in the USA.

© 2012 Biocompatibles UK Ltd. ECO12-08B (R) Rev 1.

The sizes of DC Bead used in the studies listed may not be the same as shown in this image. Link to study details for more information.